Description
Selective inhibitor of vacuolar type H+-ATPases (IC50 = 5 nM); blocks the acidification of vacuolar organelles as well as early to late endosomal transport; interferes with bone resorption, maturation of CD8 T lymphocytes, and the expression of MHC class II molecules on human B cells
Formal name: (3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)-18-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-4-[[4-O-(aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-8,10-dihydroxy-3,17-dimethoxy-5,7,9,11,13-pentamethyl-oxacyclooctadeca-3,5,13,15-tetraen-2-one
Synonyms: 8-deethyl-8-methyl-Concanamycin A|MCH 210
Molecular weight: 852.1
CAS: 81552-33-2
Purity: ≥95%
Formulation: A solid
Product Type|Biochemicals|Small Molecule Inhibitors|ATPases||Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Cell Biology|Endomembrane System & Vesicular Trafficking||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Immunology & Inflammation|Adaptive Immunity